There are 2867 resources available
Introduction and scientific background
Presenter: Erica Mayer
Session: Emerging toxicities of new anticancer therapies
Resources:
Slides
Webcast
1317MO - Non-OS endpoints in oncology: Strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients
Presenter: Aikaterini Fameli
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
455MO - NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study
Presenter: Stefan Symeonides
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Presenter: Ramon Salazar
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA8 - Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
Presenter: Toni Choueiri
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8
Presenter: Sumanta Pal
Session: Presidential Symposium III
Resources:
Slides
Webcast
Critical organ damage and late toxicities from anti-PD1
Presenter: Jarushka Naidoo
Session: Emerging toxicities of new anticancer therapies
Resources:
Slides
Webcast
887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with <sup>177</sup>Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
Presenter: Eric Baudin
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1319MO - Actual patient access to innovative medicines in six European countries
Presenter: Julie Vancoppenolle
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
456MO - METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
Presenter: Sophie Postel-Vinay
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast